Research
Liraglutide and IVF: Fertility Outcomes in PCOS
Liraglutide shows potential in enhancing IVF success rates for women with PCOS by addressing insulin resistance and improving egg quality.
June 19, 2025
·
12
Liraglutide shows potential in enhancing IVF success rates for women with PCOS by addressing insulin resistance and improving egg quality.
Liraglutide, a medication approved for diabetes and weight loss, is showing promise in improving IVF success rates for women with PCOS. Studies suggest it helps by addressing insulin resistance, reducing inflammation in the ovaries, and improving egg quality. When combined with metformin, it significantly boosts pregnancy rates compared to metformin alone.
Key findings:
Liraglutide targets both metabolic and hormonal issues, making it a potential game-changer for PCOS-related infertility. However, it requires careful planning as it’s not safe during pregnancy and may cause side effects like nausea. Further research is needed to confirm its long-term safety and effectiveness.
Clinical research has explored the impact of liraglutide on IVF outcomes in women with PCOS, revealing promising results in improving fertility and pregnancy rates.
One of the most notable studies is a pilot randomized trial by Salamun et al., which compared the combination of liraglutide and metformin to metformin alone in PCOS patients undergoing IVF. The results were striking: the combination therapy increased pregnancy rates per embryo transfer from 28.6% to 85.7% and nearly doubled the 12-month cumulative pregnancy rate from 35.7% to 69.2%.
"Preconception intervention with low-dose liraglutide added to metformin is superior to metformin alone in increasing PRs per ET and cumulative PRs in infertile obese women with PCOS, despite comparable weight reduction in both groups."
A meta-analysis of 11 randomized controlled trials, including 840 women with PCOS, supported these findings. It showed that GLP-1 receptor agonists like liraglutide improved natural pregnancy rates and menstrual cycle regularity compared to control treatments. Additionally, studies reported enhanced ovarian function, with the proportion of participants developing dominant follicles rising from 0% at baseline to 20% after treatment (P = 0.031).
Research has primarily targeted obese women with PCOS who experienced limited success with standard fertility treatments. In the Salamun study, 28 infertile obese women with PCOS were enrolled, all of whom had struggled with previous fertility therapies. Participants underwent a 12-week preconception treatment combining metformin (1,000 mg twice daily) with liraglutide (1.2 mg subcutaneously once daily) before starting IVF cycles.
The studies also focused on women with insulin resistance and metabolic disorders, common complications in PCOS-related infertility. Liraglutide's ability to improve insulin sensitivity and glucose metabolism appears to play a critical role in its fertility-enhancing effects.
Liraglutide's metabolic benefits have translated into significant improvements in IVF outcomes. In combination with metformin, the therapy resulted in a three-fold increase in pregnancy rates per embryo transfer, with rates climbing to 85.7% - a relative increase of approximately 200% per IVF attempt.
Further, liraglutide has been linked to improvements in oocyte quality and competence. Researchers suggest that liraglutide may reduce inflammation and enhance folliculogenesis within the ovarian microenvironment, paving the way for better egg quality and reproductive outcomes. Enhanced ovulation patterns also contributed to improved menstrual regularity, supporting more consistent hormonal cycles and better conditions for embryo implantation. The statistical significance of these findings (P = 0.03 for pregnancy rates per embryo transfer) underscores liraglutide's effectiveness in this challenging patient group.
Liraglutide improves fertility by addressing metabolic issues and directly supporting ovarian health in individuals with PCOS.
PCOS-related infertility often stems from metabolic dysfunction, particularly insulin resistance. Liraglutide helps tackle this root cause, leading to hormonal balance and improved fertility outcomes.
Weight Loss and Metabolic Benefits
Research shows that liraglutide significantly aids weight loss in overweight or obese women with PCOS. On average, patients experienced a weight reduction of 9.0 kg (95% CI: 7.8–10.1, p < 0.0001) and a BMI drop of 3.2 kg/m² (95% CI: 2.8–3.6, p < 0.0001). Impressively, 81.7% of participants shed over 5% of their initial weight, and 32.9% lost more than 10%. These changes were accompanied by reduced insulin resistance, as reflected in lower HOMA-IR scores (g = -0.52, 95% CI -0.83 to -0.22).
Hormonal Adjustments
Liraglutide also positively influences hormone levels. It elevates sex hormone-binding globulin (SHBG) by 7.4 nmol/L (95% CI: 4.1 to 10.7) and lowers free testosterone by 0.005 nmol/L (95% CI: -0.009 to -0.001). In a 26-week study involving 72 overweight women with PCOS, a daily dose of 1.8 mg liraglutide reduced free testosterone levels by 19%. Additionally, combining liraglutide with metformin for 12 weeks improved reproductive hormones, reducing luteinizing hormone (LH) from 9.77 ± 5.81 mIU/mL to 6.61 ± 4.72 mIU/mL (P = 0.036) and increasing progesterone from 0.54 ng/mL to 1.08 ng/mL (P = 0.020). These hormonal shifts promote ovulation, helping restore regular menstrual cycles.
Restoring Menstrual Cycles
The combined metabolic and hormonal improvements support menstrual regularity. A study reported a significant increase in menstrual frequency (effect size g = 1.76, 95% CI: 0.28–3.24), reflecting better hypothalamic-pituitary-ovarian (HPO) axis function. This is key for ovulation and successful IVF outcomes.
These metabolic and hormonal changes lay the groundwork for liraglutide’s direct impact on ovarian health.
Liraglutide doesn’t just improve metabolism - it also acts directly on ovarian tissue, enhancing fertility independently of weight loss.
Cellular-Level Improvements in the Ovary
At the cellular level, liraglutide reduces CXCL10 secretion in granulosa cells via the JAK pathway. High CXCL10 levels are linked to poor follicle growth and ovulation in PCOS. By lowering inflammatory markers like CXCL10, IL-1B, and IL-6, liraglutide creates a healthier environment within the ovary, promoting better follicular development.
Supporting Follicular Growth
By inhibiting CXCL10, liraglutide enhances oocyte maturation and cumulus expansion, both critical for ovulation. Studies have shown that while CXCL10 supplementation hinders follicle growth, liraglutide reverses these effects.
Benefits for the Endometrium
GLP-1 receptors are found throughout the female reproductive system, including the hypothalamus, pituitary, ovaries, and endometrium. In the endometrium, liraglutide may reduce inflammation and fibrosis, improving receptivity. Research in diabetic rats indicates that GLP-1 receptor agonists can combat inflammation and oxidative stress, preventing endometrial degeneration and fibrosis.
Through these targeted actions, liraglutide creates a supportive environment for reproduction, making it a promising treatment option for PCOS-related infertility.
When exploring fertility treatments for PCOS, liraglutide presents an alternative to traditional methods. Comparing it with established options like metformin and lifestyle changes helps patients and healthcare providers make better decisions.
Liraglutide has shown greater success in promoting weight loss compared to standard PCOS treatments. While lifestyle changes are typically the first step, weight loss is critical since obesity impacts 50–80% of women with PCOS. Even a modest reduction of 5–10% in body weight can significantly improve insulin resistance and hormone balance.
This medication also outperforms other weight loss treatments. For example, 76% of patients taking liraglutide 3 mg achieved weight loss exceeding 5%, compared to 30% using a placebo and 44% using orlistat. Additionally, liraglutide is more effective than metformin alone at reducing weight and improving insulin sensitivity, with fewer gastrointestinal side effects.
However, liraglutide isn't without drawbacks. Common side effects include nausea, vomiting, and diarrhea, which can make it harder for some patients to continue treatment. Its long-term safety during pregnancy is also unclear, so patients are advised to use contraception during treatment and carefully plan conception.
Here’s a quick overview of how liraglutide stacks up against other treatments:
| Treatment Comparison | Weight Loss Success (>5%) | Key Benefits | Main Drawbacks |
|---|---|---|---|
| Liraglutide | 81.7% | Superior weight loss; better insulin sensitivity | Gastrointestinal side effects; unclear pregnancy safety |
| Metformin | Lower than liraglutide | Proven safety; lower cost | Limited weight loss; gastrointestinal issues |
| Lifestyle interventions | Variable | No medication risks; overall health improvements | Hard to maintain; may not be enough on its own |
Cost is another factor to consider. Liraglutide is much more expensive than metformin or lifestyle changes, and insurance coverage can vary. Patients should also be screened for contraindications, such as a history of pancreatitis, diabetic retinopathy, or thyroid cancer.
Interestingly, combining liraglutide with metformin might offer even better results.
For PCOS patients dealing with multiple metabolic challenges, combining liraglutide with metformin tackles both insulin resistance and weight management, which can improve IVF success rates. Research indicates that this combination works better than either medication alone.
Studies have shown that pairing liraglutide with metformin significantly boosts pregnancy rates compared to using metformin by itself. This is particularly important for obese PCOS patients who haven’t responded well to metformin alone. The combination targets multiple aspects of PCOS - metformin helps with insulin resistance, while liraglutide promotes weight loss and additional metabolic improvements.
A meta-analysis of 12 randomized controlled trials involving 1,096 patients found that combining metformin with liraglutide was more effective than metformin alone. Benefits included a greater reduction in BMI, improved glucose and lipid levels, better hormone balance, more regular menstrual cycles, higher ovulation rates, and increased chances of spontaneous conception.
The weight loss results are also striking. In one study, patients on the combination therapy lost an average of 6.5 ± 2.8 kg, compared to 3.8 ± 3.7 kg with liraglutide alone and 1.2 ± 1.4 kg with metformin alone (P < 0.001).
"Our observations are not definitive, but do encourage further exploration of the impact of preconception treatment with GLP-1 receptor agonists on reproductive outcomes in different obesity-related populations."
- Mojca Jensterle Sever, MD, PhD
This combined approach offers a promising option for patients who have struggled with traditional treatments, addressing the complex metabolic and reproductive challenges associated with PCOS.
Liraglutide is showing potential in managing PCOS-related infertility, particularly in IVF treatments. However, clear clinical guidelines and additional research are necessary to optimize its use and fully understand its role in fertility care.
When considering liraglutide for fertility treatments, healthcare providers should adhere to specific protocols. For weight management, liraglutide 3.0 mg is prescribed alongside diet and exercise for patients with a BMI of 30 kg/m² or higher, or 27 kg/m² and above if comorbidities are present. Studies suggest that combining liraglutide (1.2 mg) with metformin may enhance pregnancy rates after IVF in women with PCOS and infertility.
Liraglutide is administered as a daily subcutaneous injection, typically in the abdomen, thigh, or upper arm. To minimize gastrointestinal side effects, the dosage starts at 0.6 mg and increases weekly by 0.6 mg until reaching 3.0 mg.
Patient selection is critical. OBGYNs should actively engage in discussions about body weight and identify suitable weight-management strategies. Liraglutide is not recommended for patients with a personal or family history of thyroid C cell tumors and is contraindicated during pregnancy. If a patient does not achieve at least a 4% weight loss after 16 weeks, discontinuation should be considered.
Proper training for staff on injection devices is essential, as is providing patients with a dedicated support contact. To help manage side effects, patients should be advised to eat small, frequent meals and chew thoroughly. Regular follow-ups are key, with monthly check-ins initially, transitioning to every three months to monitor progress in areas like nutrition, exercise, sleep, and stress management.
While these protocols provide a foundation for current use, many questions remain unanswered.
Although initial findings are promising, more research is needed to refine treatment protocols and address lingering uncertainties. Large-scale, well-structured randomized controlled trials (RCTs) are essential to establish standardized definitions for reproductive outcomes like ovulation, pregnancy, and live births. A meta-analysis of 11 RCTs involving 840 women with PCOS indicated that GLP-1 receptor agonists can improve natural pregnancy rates and menstrual regularity, but larger studies are needed to confirm these results.
Further studies should explore the long-term effects and safety of liraglutide across different PCOS phenotypes and weight categories. Investigating the mechanisms through which GLP-1 impacts ovarian function could lead to more precise treatment approaches and better patient selection. Research into optimal dosing, treatment duration, and combination therapies - such as those with insulin sensitizers or ovulation inducers - is also crucial. Comparative studies with other GLP-1 receptor agonists and comprehensive long-term safety data will be vital, especially as these medications are considered for women planning pregnancies.
For women navigating fertility challenges linked to PCOS, staying informed about the latest research and treatments is essential. PCOSHelp is dedicated to providing evidence-based information and resources to support effective PCOS management. The platform offers comprehensive guides on improving fertility and understanding medication options, empowering patients to collaborate with their healthcare providers. As research on liraglutide and IVF outcomes progresses, PCOSHelp ensures access to reliable, up-to-date information, helping women make informed decisions to enhance fertility outcomes.
The current research highlights liraglutide's promising role in improving fertility outcomes for PCOS patients undergoing IVF treatments. Studies show that combining liraglutide with standard care can lead to better pregnancy rates, offering hope for individuals who have struggled with traditional approaches.
For instance, Salamun et al. found that adding liraglutide to metformin therapy significantly boosted pregnancy rates per embryo transfer compared to using metformin alone. This improvement is tied to liraglutide's dual benefits: addressing the metabolic challenges linked to PCOS while also reducing inflammation in the ovarian environment, which can enhance oocyte quality and follicular development.
Clinical evidence particularly supports liraglutide's effectiveness in obese PCOS patients, a group often resistant to conventional fertility treatments. However, personalized care remains essential. Physicians must consider each patient's unique metabolic and reproductive profile to determine the best course of action.
Despite the encouraging results, there are critical factors to keep in mind. Liraglutide is not safe to use during pregnancy, requiring careful planning and a washout period before trying to conceive. Additionally, while the current findings are promising, larger randomized controlled trials are necessary to establish standardized treatment protocols and confirm long-term safety.
The future of PCOS fertility treatment seems to be shifting toward more holistic and tailored strategies that address both metabolic and reproductive health. With ongoing research, liraglutide has the potential to become a central part of this approach, offering new hope for improved reproductive outcomes.
For women facing these complex choices, staying informed about the latest advancements and collaborating with knowledgeable healthcare providers is key to achieving the best results. At PCOSHelp, we remain committed to delivering up-to-date, evidence-based insights to support effective PCOS management.
Liraglutide, a type of GLP-1 receptor agonist, shows potential in boosting IVF success rates for women with PCOS by tackling several fertility-related challenges. It aids in weight management, improves insulin sensitivity, and helps regulate menstrual cycles - all crucial factors for enhancing ovarian response and implantation success.
Research indicates that liraglutide may be especially helpful for women with PCOS who are obese or have faced difficulties with other fertility treatments. By improving metabolic health and hormonal stability, it creates a more supportive environment for conception during IVF.
Common side effects of liraglutide when used in fertility treatments for PCOS include nausea, vomiting, diarrhea, and constipation. These issues are most common during the early stages of treatment as the body adjusts to the medication. Fortunately, these symptoms are usually temporary and can often be managed by slowly increasing the dosage and offering supportive care.
Beyond its side effects, the weight loss associated with liraglutide use may help improve ovarian function, which could alleviate some PCOS-related symptoms. To ensure the best outcomes and reduce discomfort, regular monitoring and tailored dose adjustments are crucial for women incorporating liraglutide into their fertility treatment plan.
Combining liraglutide with metformin has proven effective in improving IVF success rates for women with PCOS by targeting critical factors that influence fertility. This combination works to regulate blood sugar and lipid levels, lower excess sex hormones, and enhance ovarian function - key elements that support ovulation and boost the likelihood of pregnancy.
In addition, this approach often results in more significant weight loss and better hormonal balance, which are particularly crucial for obese women with PCOS undergoing IVF. These combined benefits lead to higher clinical pregnancy rates and better overall reproductive outcomes.
